

## ASX Announcement

### US patent allowance for Imugene's onCARlytics

---

- Core US patent allowed in major oncology market
- Patent provides method of composition and method of use protection to August 10, 2038

**Sydney, Australia, 18 June 2025:** Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application number 16/637,909 which protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR T cell therapies.

The patent titled “ONCOLYTIC VIRUS EXPRESSING A CAR T CELL TARGET AND USES THEREOF” (inventors Yuman Fong, Saul Priceman, Stephen Forman, Nanhai Chen and Anthony Park from the City of Hope) protects the method of composition and method of use of Imugene's onCARlytics technology through to August 10 2038.

Exclusively licensed to Imugene, onCARlytics is a CD19-expressing oncolytic virus that enters solid tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies such as CAR T cellular therapies.

Imugene's ongoing OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the United States, with up to approximately 40 patients proposed to take part in the trial.

Leslie Chong, Managing Director and CEO of Imugene, said:

“Imugene receiving this US patent allowance for the CF33-CD19 onCARlytics platform is a crucial step forward for our IP position, with the US being the largest healthcare market in the world. This follows patent allowance in China, an equally large cell therapy market, earlier in 2025.”



For more information please contact:

**Leslie Chong**

**Managing Director and Chief Executive Officer**

info@imugene.com

**General Investor Enquiries**

shareholderenquiries@imugene.com

**Media Enquiries**

Matt Wright

matt@nwrcommunications.com.au

Connect with us on LinkedIn @Imugene Limited

Follow us on Twitter @TeamImugene

Watch us on YouTube @ImugeneLimited

**About Imugene (ASX:IMU)**

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies.

Our pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. Our pipeline also includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing novel cancer therapies that are currently marketed globally.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading



specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

*Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.*